2 results
Approved WMOWill not start
This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 in subjects 18 years and older with RR DLBCL, including those with MYC Alterations.
Approved WMORecruiting
1) To determine whether advanced MRI techniques can detect active inflammatory Gd enhancing lesions. 2) To determine whether blood biomarkers are associated with the presence of enhancing brain lesions in MS. 3) To determine whether advanced MRI…